Rocket Pharmaceuticals Inc (RCKT) - Total Assets
Based on the latest financial reports, Rocket Pharmaceuticals Inc (RCKT) holds total assets worth $368.03 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Rocket Pharmaceuticals Inc's book value for net asset value and shareholders' equity analysis.
Rocket Pharmaceuticals Inc - Total Assets Trend (2012–2024)
This chart illustrates how Rocket Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data.
Rocket Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Rocket Pharmaceuticals Inc's total assets of $368.03 Million consist of 71.7% current assets and 28.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 31.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $25.15 Million | 4.8% |
| Goodwill | $39.15 Million | 7.4% |
Asset Composition Trend (2012–2024)
This chart illustrates how Rocket Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Rocket Pharmaceuticals Inc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Rocket Pharmaceuticals Inc's current assets represent 71.7% of total assets in 2024, a decrease from 99.7% in 2012.
- Cash Position: Cash and equivalents constituted 31.0% of total assets in 2024, down from 96.6% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is goodwill at 7.4% of total assets.
Rocket Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Rocket Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
Rocket Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.30 | 6.05 | 14.94 |
| Quick Ratio | 7.30 | 6.05 | 14.94 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $196.51 Million | $201.77 Million | $454.73 Million |
Rocket Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Rocket Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.13 |
| Latest Market Cap to Assets Ratio | 0.73 |
| Asset Growth Rate (YoY) | -6.8% |
| Total Assets | $527.70 Million |
| Market Capitalization | $385.27 Million USD |
Valuation Analysis
Below Book Valuation: The market values Rocket Pharmaceuticals Inc's assets below their book value (0.73x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Rocket Pharmaceuticals Inc's assets decreased by 6.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Rocket Pharmaceuticals Inc (2012–2024)
The table below shows the annual total assets of Rocket Pharmaceuticals Inc from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $527.70 Million | -6.82% |
| 2023-12-31 | $566.34 Million | +2.63% |
| 2022-12-31 | $551.81 Million | +11.02% |
| 2021-12-31 | $497.02 Million | -15.88% |
| 2020-12-31 | $590.82 Million | +58.77% |
| 2019-12-31 | $372.12 Million | +48.07% |
| 2018-12-31 | $251.31 Million | +146.92% |
| 2017-12-31 | $101.78 Million | -21.50% |
| 2016-12-31 | $129.65 Million | +14.41% |
| 2015-12-31 | $113.32 Million | +1952.92% |
| 2014-12-31 | $5.52 Million | -57.09% |
| 2013-12-31 | $12.86 Million | +805.21% |
| 2012-12-31 | $1.42 Million | -- |
About Rocket Pharmaceuticals Inc
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States. It develops vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (… Read more